Silo Pharma, Inc. is a developmental-stage biopharmaceutical company focused on developing novel therapeutics for underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. The company’s pipeline includes SPC-15, an intranasal serotonin 4 receptor agonist for PTSD and anxiety; SP-26, a ketamine-based time-release implant for chronic pain and fibromyalgia; SPC-14, a compound targeting Alzheimer’s disease; and SPU-16, a CNS-homing peptide for multiple sclerosis. Silo Pharma utilizes psychedelic formulations, such as ketamine and psilocybin, alongside conventional drugs, and pursues the FDA’s 505(b)(2) regulatory pathway to expedite approval. The company holds exclusive license agreements with Columbia University and the University of Maryland, Baltimore, and has licensed soft mist nasal spray technology from Medspray Pharma BV. Additionally, the company operates a cryptocurrency treasury business and offers QwikAgents, a service for personal AI agents.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage silopharma.com
Sector Healthcare IR page ir.silopharma.com
Tags
neuropsychiatry, psychedelic medicine, intranasal delivery, chronic pain, alzheimer's disease, multiple sclerosis, ketamine, cryptocurrency treasury, ai agents, SPC-15, SP-26, SPC-14, SPU-16, QwikAgents, Medspray Pharma BV, Columbia University, University of Maryland Baltimore
Press page —

Metrics

Valuation  
Market cap $ 2.849M
Market cap (USD) $ 2.849M
P/E -1.44
PEG —
P/BV 0.34
P/S 39.52
P/OCF -0.95
P/FCF -0.54
Dividend yield —
Turnover / mcap —
Returns  
ROE -74.6%
ROI -67.0%
ROIC -50.9%
Profit margin -5,863.5%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 35
Quality score -55.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2013 FY 2012 FY 2011
Revenue 72.102K 72.102K 72.102K 72.102K 71.264K 40.923K 40.569K — — — — —
Net profit -4.228M -4.393M -3.701M -3.909M 3.904M -3.038M -1.013M -969.463K 356.536K — -39.446K -49.803K
Free cash flow -5.236M -3.834M -3.224M -3.498M -2.278M — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2013 FY 2012 FY 2011
Share price 0.42 0.84 1.61 2.72 0.14 — 0.45 — — — — —
Price performance 12m -0.51 -0.48 -0.41 18.43 — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — 23,500 — 66,010 — — —
Cash and deposits (USD) 579,209 294,591 336,679 111,752 1.13M 9.84M 11.4M 3.52M 3.91M 4.75M
Intangible assets (USD) — — 29,440 — — — — — 241,215 217,375
Cash flow detail
Operating cash flow (USD) -143,555 -284,618 272,637 -794,324 -1.16M -2.28M -3.5M -3.22M -3.83M -4.66M
Change in receivables (cash effect) (USD) — — — — — -1,210 -4,800 -3,590 — —
Change in inventories (cash effect) (USD) — — -26,973 -129,393 -15,065 — — — — —
Change in payables (cash effect) (USD) -37,658 -14,755 -12,712 29,231 72,525 291,050 -53,721 339,272 633,007 -993,414
Interest paid (cash effect) (USD) — — — — -224 — -2,199 -4,869 -5,084 -37,302
Income taxes paid (cash effect) (USD) -250 — — — — — -25,159 — — —
Share-based compensation (USD) — 177,500 145,000 319,587 755,993 395,123 577,651 871,625 906,773 117,021
Operating cash flow before change in receivables (USD) — — — — — -2.28M -3.49M -3.22M — —
Income detail
Research and development expense (USD) — — — — 26,250 693,910 1.29M 845,092 2.37M 2.16M
↳ 5y CAGR +141.6%
Total comprehensive income (USD) — — — — — — -3.91M -3.71M -4.38M -4.22M
Comprehensive income to owners (USD) — — — — — — -3.91M -3.71M -4.38M -4.22M
Provision for credit losses (USD) 0.00 62,910 35,000 — 165,376 -148,500 -20,000 — — —
Reported Nov 14, 2018 Apr 4, 2019 Apr 4, 2019 Mar 20, 2020 Mar 28, 2022 Mar 28, 2022 Mar 25, 2024 Mar 25, 2024 Mar 28, 2025 Mar 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On November 5, 2026, Silo Pharma, Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain accredited investors (“the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of (i) 136,005 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”) at a purchase price of $1.50 per Share and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 430,661 shares of Common Stock (the “Pre-Funded Warrant Shares”) at a purchase price of $1.4999 per Pre-Funded Warrant. The Shares, the Pre-Funded Warrants, and the Pre-Funded Warrant Shares are collectively referred to herein as the “Securities.”

The Pre-Funded Warrants are immediately exercisable and may be exercised at a nominal exercise price of $0.0001 per share of Common Stock at any time until all of the Pre-Funded Warrants are exercised in full. A holder may not exercise any portion of the Pre-Funded Warrants to the extent the Purchaser would own more than 4.99% of the outstanding Common Stock immediately after exercise.

On October 13, 2026, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Larry King (the “Seller”). Pursuant to the Agreement, the Seller agreed to sell, and the Company agreed to purchase, certain software and related intellectual property (the “Purchased Assets”).

In consideration for the Purchased Assets, the Company issued to the Seller, 150,000 shares of its common stock, par value $0.0001 per share (the “Shares”). The Shares are subject to a lock-up period beginning on the effective date of the Agreement and ending on the earlier of (i) twelve (12) months after such date, (ii) a Change in Control, as defined in the Agreement, or (iii) written consent of the Company (the “Lock Up Period”). During the Lock Up Period, the Seller may not, without the Company’s prior written consent, directly or indirectly, offer, sell, contract to sell, hedge, pledge, grant any option, right or warrant to purchase, or otherwise transfer or dispose of any of the Shares, or enter into any swap or other agreement or transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of any of the Shares.

On October 1, 2026, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Norsight Consulting Inc., an Arkansas corporation (the “Seller”). Pursuant to the Agreement, the Seller agreed to sell, and the Company agreed to purchase, certain software, technology, and related intellectual property, including related trademarks, domain names, data, trade secrets and other intellectual property rights (the “Purchased Assets”).

In consideration for the Purchased Assets, the Company issued to the Seller a warrant (the “Warrant”) to purchase up to 300,000 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”). The Warrant has an exercise price of $1.51 per share and includes a cashless exercise feature. The Warrant is exercisable beginning April 1, 2027 and will expire on September 30, 2031. The Seller may not exercise any portion of the Warrant to the extent the Seller would own more than 4.99% of the outstanding Common Stock immediately after exercise.

Prompts

Silo Pharma, Inc. (ticker SILO), listed in United States.

Company History

Date Change Detail
Oct 6, 2020 Renamed UPPERCUT BRANDS, INC. → SILO PHARMA, INC.
Aug 13, 2019 Renamed POINT CAPITAL, INC. → UPPERCUT BRANDS, INC.
Jan 30, 2013 Renamed GOLD SWAP INC → POINT CAPITAL, INC.

ETFs Holding Silo Pharma, Inc.

ETF Weight in ETF Shares Market value As of
PSIL 0.42% 96,113 $ 161.47K Nov 17, 2026